Ribonucleotide Reductase in Hepatoblastoma Progression and Drug Resistance

核糖核苷酸还原酶在肝母细胞瘤进展和耐药性中的作用

基本信息

  • 批准号:
    10320059
  • 负责人:
  • 金额:
    $ 24.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-01-01 至 2023-12-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Hepatoblastoma (HB) is a rare liver cancer that occurs exclusively in young children. Although most HB tumors can be removed by surgery after chemotherapy, a small number of HB patients do develop recurrent or metastatic disease following standard treatment and their survival is poor. Since clinical trials are limited due to the rareness of this cancer, basic research is needed to understand the biology responsible for HB progression and drug resistance in order to develop more effective treatment. Our recent study found ribonucleotide reductase (RNR), an enzymatic complex catalyzing the formation of deoxyribonucleotides for DNA replication and repair, is significantly upregulated in high-risk HB. The active RNR complex is a heterodimeric tetramer constructed by a large RNR1 subunit and one of the two small RNR2 subunits, RRM2 or RRM2B. RRM2 is the dominant RNR2 subunit in dividing cells and is associated with the prognosis of many solid tumors in adults. RRM2B is expressed low in cancer cells in general but can be induced under stressful conditions. Our preliminary study showed that RRM2 knockdown significantly inhibited HB cell growth, and more interestingly, treating HB cells with standard chemotherapy induced a significant upregulation of RRM2B. In patient tumors removed after chemotherapy, there was also a much higher level of RRM2B in the high-risk tumors compared to the low-risk tumors. Thus, we hypothesize that the subunit switching from RRM2 to RRM2B during chemotherapy is a key mechanism through which HB cells retain RNR activity to promote drug resistance. Therefore, RNR can be a potential therapeutic target for high-risk and refractory HB. We propose to test this hypothesis by examining the switching and specific function of RRM2 and RRM2B in HB progression and drug resistance, testing the efficacy of existing RRM2 inhibitors in combination with chemotherapy in vitro and in vivo, and use a high-throughput approach to screen drugs that can effectively degrade RRM2B in HB cells. The success of this project will unfold the dynamics of RNR complex during HB development and adaption to chemotherapy, and provide scientific evidence supporting RNR as a new therapeutic target for high-risk and refractory HB.
项目摘要 肝母细胞瘤(HB)是一种罕见的肝癌,仅发生在幼儿中。虽然大多数HB 化疗后肿瘤可以通过手术切除,少数HB患者会复发 或转移性疾病,并且它们的存活率很差。由于临床试验有限 由于这种癌症的罕见性,需要进行基础研究以了解HB的生物学机制 进展和耐药性,以便开发更有效的治疗方法。我们最近的研究发现 核糖核苷酸还原酶(RNR),催化脱氧核糖核苷酸形成的酶复合物, DNA复制和修复在高危HB中显着上调。活性RNR复合物是一种 由一个大的RNR1亚基和两个小的RNR2亚基之一RRM2构建的异二聚体四聚体 或RRM2B。RRM2是分裂细胞中的主要RNR 2亚基,与肿瘤的预后相关。 成年人中的许多实体瘤。RRM2B通常在癌细胞中表达较低,但可以在肿瘤细胞中诱导表达。 紧张的条件。我们的初步研究表明,RRM2基因的敲低显著抑制了HB细胞的生长, 生长,更有趣的是,用标准化疗治疗HB细胞诱导了显著的 RRM2B的上调。在化疗后切除的患者肿瘤中, RRM2B在高风险肿瘤中的表达与低风险肿瘤相比。因此,我们假设亚基 在化疗期间从RRM2转换为RRM2B是HB细胞保留 RNR活性促进耐药性。因此,RNR可能是高风险的潜在治疗靶点。 和难治性HB。我们建议通过检查开关和特定功能来测试这一假设, RRM2和RRM2B在HB进展和耐药性中的作用,测试现有RRM2抑制剂在 在体外和体内与化疗联合,并使用高通量方法筛选药物, 可有效降解HB细胞中的RRM2B。该项目的成功将展现RNR的动态 复杂的HB发展和适应化疗,并提供科学证据支持 RNR作为高危和难治性HB的新治疗靶点

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse.
  • DOI:
    10.1038/s42003-023-04630-7
  • 发表时间:
    2023-03-08
  • 期刊:
  • 影响因子:
    5.9
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Liqin Zhu其他文献

Liqin Zhu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Liqin Zhu', 18)}}的其他基金

Ribonucleotide Reductase in Hepatoblastoma Progression and Drug Resistance
核糖核苷酸还原酶在肝母细胞瘤进展和耐药性中的作用
  • 批准号:
    10112404
  • 财政年份:
    2021
  • 资助金额:
    $ 24.67万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.67万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 24.67万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 24.67万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 24.67万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 24.67万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 24.67万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 24.67万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 24.67万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 24.67万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 24.67万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了